GE's Clarient Purchase Heightens Company's Focus on Tests for Cancer Drug Personalization
October 27, 2010
GE's Clarient Purchase Heightens Company's Focus on Tests for Cancer Drug Personalization
GE Healthcare continues to grow its presence in personalized medicine through its recent purchase of Clarient, which has assets in oncology molecular diagnostics and companion tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GE's Clarient to be Key Beneficiary of $1B Bid to Bolster Molecular Dx Presence in Oncology
September 21, 2011 / Pharmacogenomics Reporter - Dx Focus: Clarient to Offer Qiagen Therascreen KRAS Test as Erbitux CDx
January 31, 2013 / PCR Insider - MDx/CDx Focus: MolecularMD Grabs LKB1 Rights; Clarient Offering Qiagen KRAS Test; Inform's OnPART
January 30, 2013 / Pharmacogenomics Reporter - GE Healthcare Acquires SeqWright to Add NGS Capabilities to Clarient Cancer Dx Business
April 11, 2012 / Clinical Sequencing News - Clarient, Acorn Team Up on Tumor Molecular Testing
December 9, 2011 / GenomeWeb Daily News